We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Ardelyx Inc (ARDX) reports significant revenue increases for IBSRELA and XPHOZAH, while navigating operational challenges and investing in future growth.
Moby summary of Ardelyx, Inc.'s Q1 2026 earnings call
Michael Raab: Thank you. At Ardelyx, we are building an innovative pipeline of medicines for patients with unmet medical needs. As we build on this momentum, our focus is on executing on our four key priorities: accelerating the growth of Ibsrela, maintaining the Exposa momentum, building and expanding our pipeline, and delivering strong financial results.
Ardelyx (ARDX) delivered earnings and revenue surprises of -15.39% and +3.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with “another significant year of growth” underway, highlighting strong first-quarter demand for its IBS-C product IBSRELA and continued momentum for kidney disease drug XPHOZAH, while also advancing pipeline efforts aimed at expanding t